肝细胞癌转化治疗的现状与展望

doi:10.16139/j.1007-9610.2022.02.010

摘要/Abstract

中图分类号:

R735.7

孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.

SUN Huichuan. Current status and perspectives of conversion therapy for hepatocellular carcinoma[J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 134-138.

参考文献 38

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338 URL
[3]	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1 URL
[4]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6. doi: 10.1038/s41572-020-00240-3 pmid: 33479224
[5]	Hermann RE, Lonsdale D. Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: report of a survival[J]. Surgery, 1970, 68(2):383-388.
[6]	Tang ZY, Liu KD, Bao YM, et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection[J]. Cancer, 1990, 65(2):211-215. pmid: 1688507
[7]	Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimoda-lity treatment[J]. Ann Surg, 1993, 217(2):149-154. pmid: 8382468
[8]	Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6):674-678. doi: 10.1159/000018676 URL
[9]	Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma[J]. Ann Surg, 2004, 240(2):299-305. doi: 10.1097/01.sla.0000133123.11932.19 URL
[10]	Zhang Y, Huang G, Wang Y, et al. Is Salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? ten years of experience[J]. Oncologist, 2016, 21(12):1442-1449. doi: 10.1634/theoncologist.2016-0094 URL
[11]	Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients[J]. World J Surg, 1995, 19(6):784-789. pmid: 8553666
[12]	赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. 中国医学科学院学报, 2009, 31(4):503-505.
[13]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905. doi: 10.1056/NEJMoa1915745 URL
[14]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable he-patocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7 URL
[15]	Zhu AX, Finn RS, Ikeda M, et al. A phase Ⅰb study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15_suppl):4519. doi: 10.1200/JCO.2020.38.15_suppl.4519 URL
[16]	Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4):320-329. doi: 10.1159/000514313 URL
[17]	Zhang W, Hu B, Han J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients[J]. Front Oncol, 2021, 11(4082):747950.
[18]	Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4):434-442. doi: 10.21037/hbsn-21-188 URL
[19]	Zhang J, Zhang X, Mu H, et al. Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study[J]. Front Oncol, 2021, 11:729764.
[20]	Shindoh J, Kawamura Y, Kobayashi Y, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma[J]. Ann Surg Oncol, 2021, 28(12)7663-7672. doi: 10.1245/s10434-021-09974-0 URL
[21]	Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9):891-903. doi: 10.1038/s43018-021-00234-4 URL
[22]	Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study[J]. J Hepatol, 2019, 70(5):893-903. doi: 10.1016/j.jhep.2019.01.013 URL
[23]	Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study[J]. Cancers (Basel), 2019, 11(8):1084. doi: 10.3390/cancers11081084 URL
[24]	Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity ma-thching score analysis[J]. Medicine (Baltimore), 2016, 95(11):e3015.
[25]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2):143-168.
[26]	孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6):618-632.
[27]	Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970. doi: 10.1200/JCO.20.00808 URL
[28]	Kudo M, Ikeda M, Motomura K, et al. A phase Ⅰb study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(4_suppl):513.
[29]	Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319):1734-1739. pmid: 12049862
[30]	Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5):1164-1171. doi: 10.1053/jhep.2002.33156 URL
[31]	Orlacchio A, Chegai F, Merolla S, et al. Downstaging di-sease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization[J]. World J Hepatol, 2015, 7(12):1694-1700. doi: 10.4254/wjh.v7.i12.1694 pmid: 26140089
[32]	Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478. doi: 10.1007/s00280-018-3638-0 URL
[33]	Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69. doi: 10.1016/j.jhep.2018.02.008 URL
[34]	Kamiyama T, Nakanishi K, Yokoo H, et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma[J]. Int J Clin Oncol, 2007, 12(5):363-368. doi: 10.1007/s10147-007-0701-y pmid: 17929118
[35]	Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepato-cellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151. doi: 10.1200/JCO.18.02184 URL
[36]	Yarchoan M, Zhu Q, Durham JN, et al. Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2021, 39(3_suppl):335.
[37]	Zhang W, Hu B, Han J, et al. A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: a prospective, non-randomized, open-label cohort study[J]. Ann Oncol, 2020, 31:S1307.
[38]	Dhir M, Sasson AR. Surgical management of liver metastases from colorectal cancer[J]. J Oncol Pract, 2016, 12(1):33-39. doi: 10.1200/JOP.2015.009407 URL

肝细胞癌转化治疗的现状与展望

Current status and perspectives of conversion therapy for hepatocellular carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	卢一鸣, 熊建平, 田艳涛. 晚期胃癌转化治疗的发展现状与研究前景[J]. 外科理论与实践, 2023, 28(01): 17-23.
[2]	刘文韬, 刘福坤. 中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41.
[3]	任新平, 李军建, 张杰, 詹维伟. 超声造影在肝局灶性病变诊疗中的应用进展[J]. 诊断学理论与实践, 2022, 21(06): 684-690.
[4]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[5]	方诚, 夏勇, 王葵, 沈锋. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27(02): 107-112.
[6]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[7]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[8]	马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[9]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[10]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[11]	吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.
[12]	张景辉, 徐袁, 印慨. 胃癌腹膜转移的诊断和相关治疗[J]. 外科理论与实践, 2021, 26(01): 28-33.
[13]	闫梓乔, 周继点, 易黎, 洪永刚, 刘启志, 辛诚. 巨大骶前囊肿的外科诊治（附1例报告）[J]. 外科理论与实践, 2020, 25(01): 77-78.
[14]	黄成, 孙惠川. 《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(01): 6-9.
[15]	朱正纲. 晚期胃癌转化治疗的难点、焦点与要点[J]. 外科理论与实践, 2019, 24(01): 1-5.